Hyaluronan dry powder inhalation - TFF Pharmaceuticals
Alternative Names: Hyaluronan inhalation powder - TFF PharmaceuticalsLatest Information Update: 30 Jun 2023
Price :
$50 *
At a glance
- Originator TFF Pharmaceuticals
- Developer TFF Pharmaceuticals; University of Texas
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Respiration disorders
Most Recent Events
- 04 May 2023 TFF Pharmaceuticals establishes CRADA with The National Institute of Environmental Health Sciences (NIEHS) for the development of Hyaluronan dry powder inhalation in Respiratory disorders
- 04 May 2023 Early research in Respiration disorders (Prevention) in USA (Inhalation)
- 04 May 2023 Early research in Respiration disorders in USA (Inhalation)